HC Wainwright Equities Analysts Decrease Earnings Estimates for Oncolytics Biotech Inc. (NASDAQ:ONCY)


Oncolytics Biotech Inc. (NASDAQ:ONCYFree Report) – Equities researchers at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Tuesday, May 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.42 for the year, down from their prior forecast of $0.44. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.32) per share.

Separately, Raymond James started coverage on Oncolytics Biotech in a report on Thursday, April 4th. They set an “outperform” rating and a $3.00 price objective on the stock.

Get Our Latest Stock Analysis on ONCY

Oncolytics Biotech Stock Performance

Shares of NASDAQ ONCY opened at $1.16 on Wednesday. The firm has a market cap of $87.99 million, a price-to-earnings ratio of -3.87 and a beta of 1.91. The business’s 50-day simple moving average is $1.09 and its 200-day simple moving average is $1.22. Oncolytics Biotech has a 52 week low of $0.88 and a 52 week high of $3.39.

Oncolytics Biotech (NASDAQ:ONCYGet Free Report) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07.

Institutional Trading of Oncolytics Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ausdal Financial Partners Inc. acquired a new position in shares of Oncolytics Biotech during the third quarter worth approximately $44,000. Advisor Resource Council acquired a new stake in shares of Oncolytics Biotech in the fourth quarter worth $135,000. Finally, International Assets Investment Management LLC grew its stake in shares of Oncolytics Biotech by 33.9% in the fourth quarter. International Assets Investment Management LLC now owns 269,699 shares of the company’s stock worth $364,000 after acquiring an additional 68,246 shares during the last quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

See Also

Earnings History and Estimates for Oncolytics Biotech (NASDAQ:ONCY)



Receive News & Ratings for Oncolytics Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Oncolytics Biotech and related companies with MarketBeat.com’s FREE daily email newsletter.


Source link

Check Also

VWO: Simple Emerging Market Equities ETF, But Better Choices Out There (NYSEARCA:VWO)

tum3123 The Vanguard FTSE Emerging Markets Index Fund ETF Shares (NYSEARCA:VWO) is the largest emerging …

Leave a Reply

Your email address will not be published. Required fields are marked *